Skip to content
DataLookout
Menu

NCT07140393

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary endpoints: details revised at 1 of 5 entries Show 4 more changesShow less
    • Eligibility criteria expanded, about 3 words
    • Interventions modified
    • Trial arms changed: 9 → 10
    • Secondary endpoints: 11 to 12
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Start date changed from estimate of Oct 2025 to Oct 28, 2025
    • Interventions: HRS-4508+ Capecitabine (Drug), HRS-4508+ Trastuzumab (Drug), HRS-4508+ Trastuzumab+ Capecitabine (Drug), HRS-4508+ Trastuzumab+ Pertuzumab… to HRS-4508+ Capecitabine (Drug), HRS-4508+ Trastuzumab (Drug), HRS-4508+ Trastuzumab + Nab-paclitaxel (Drug), HRS-4508+ Trastuzumab+…
    • Secondary endpoints: 10 to 11
    • Site details revised
    • Study arms: 6 to 9
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

HRS4508 DLT
Timeframe: 3 weeks
HRS4508 MTD
Timeframe: 12 weeks
HRS4508 RP2D
Timeframe: 12 weeks
The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)
Timeframe: 2 years
Objective response rate (ORR)
Timeframe: 1 year

Secondary (12)

Blood concentrations of HRS-4508
Blood concentrations of SHR-A1811
Blood concentrations of Capecitabine
Objective response rate (ORR)
Best overall efficacy (BOR)
Show 7 moreShow less
Duration of response (DoR)
Progression free survival (PFS)
Disease control rate (DCR)
Overall survival (OS)
The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)
Blood concentrations of Paclitaxel for Injection
Blood concentrations of Docetaxel

Arms and interventions

HRS-4508+ CapecitabineExperimental
HRS-4508+ TrastuzumabExperimental
HRS-4508+ Trastuzumab+ PertuzumabExperimental
HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxelExperimental
HRS-4508+ Trastuzumab + Nab-paclitaxelExperimental
HRS-4508+ Trastuzumab+ CapecitabineExperimental
Trastuzumab+ CapecitabineActive comparator
Trastuzumab+ PertuzumabActive comparator
HRS-4508+SHR-A1811Experimental
HRS-4508+ Trastuzumab+ Pertuzumab+ Docetaxel+ CarboplatinExperimental

Drugs: HRS-4508+ Capecitabine, HRS-4508+ Trastuzumab, HRS-4508+ Trastuzumab+ Pertuzumab, HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel, HRS-4508+ Trastuzumab + Nab-paclitaxel, HRS-4508+ Trastuzumab+ Capecitabine, Trastuzumab+ Capecitabine, Trastuzumab+ Pertuzumab, HRS-4508+SHR-A1811, HRS-4508+ Trastuzumab+ Pertuzumab+ Docetaxel+ Carboplatin

Sites

1 site in 1 country

  • Cancer Hospital Chinese Academy of Medical ScienceBeijing, Beijing Municipality, China